{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:10:32Z","timestamp":1780463432182,"version":"3.54.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1097\/igc.0b013e31821a3726","type":"journal-article","created":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T03:24:35Z","timestamp":1306898675000},"page":"852-858","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Human Epididymis Protein 4 (HE4) as a Serum Tumor Biomarker in Patients With Ovarian Carcinoma"],"prefix":"10.1016","volume":"21","author":[{"given":"Xiaohong","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yexia","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lirong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinping","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"As","family":"Tianyun Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"As","family":"Jun Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/IGC.0b013e31821a3726_bb0005","unstructured":"American Cancer Cancer facts and figures 2010. American Cancer Society, Surveillance and Health Policy Research, 2010. Available at: http:\/\/www.cancer.org\/acs\/groups\/content\/ @epidemiologysurveilance\/documents\/document\/ acspc-026238.pdf. Accessed January 11, 2011."},{"key":"10.1097\/IGC.0b013e31821a3726_bb0010","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/ijc.10250","article-title":"Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene","volume":"98","author":"Yin","year":"2002","journal-title":"Int J Cancer."},{"key":"10.1097\/IGC.0b013e31821a3726_bb0015","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ygyno.2006.02.024","article-title":"Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer","volume":"103","author":"Markman","year":"2006","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e31821a3726_bb0020","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1006\/gyno.2002.6603","article-title":"The significance of serum CA 125 elevation in malignant and nonmalignant diseases","volume":"85","author":"Sjovall","year":"2002","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e31821a3726_bb0025","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/ncponc0906","article-title":"Ovarian cancer: challenges of early detection","volume":"4","author":"Menon","year":"2007","journal-title":"Nat Clin Pract Oncol."},{"key":"10.1097\/IGC.0b013e31821a3726_bb0030","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ygyno.2005.08.038","article-title":"CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer","volume":"100","author":"Olivier","year":"2006","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e31821a3726_bb0035","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1373\/clinchem.2010.153122","article-title":"CA125 immune complexes in ovarian cancer patients with low CA125 concentrations","volume":"56","author":"Cramer","year":"2010","journal-title":"Clin Chem."},{"key":"10.1097\/IGC.0b013e31821a3726_bb0040","first-page":"414","volume":"18","author":"Kobayashi","year":"2008","journal-title":"A randomized study of screening for ovarian cancer: a multicenter study in Japan Int J Gynecol Cancer."},{"key":"10.1097\/IGC.0b013e31821a3726_bb0045","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-1-4757-3587-1_3","article-title":"Early detection of ovarian cancer: promise and reality","volume":"107","author":"Bast","year":"2002","journal-title":"Cancer Treat Res."},{"key":"10.1097\/IGC.0b013e31821a3726_bb0050","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1586\/erm.09.39","article-title":"HE4 as a biomarker for ovarian and endometrial cancer management","volume":"9","author":"Li","year":"2009","journal-title":"Expert Rev Mol Diagn."},{"key":"10.1097\/IGC.0b013e31821a3726_bb0055","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0378-1119(99)00342-X","article-title":"Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas","volume":"238","author":"Schummer","year":"1999","journal-title":"Gene."},{"key":"10.1097\/IGC.0b013e31821a3726_bb0060","first-page":"3695","article-title":"The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma","volume":"63","author":"Hellstrom","year":"2003","journal-title":"Cancer Res."},{"key":"10.1097\/IGC.0b013e31821a3726_bb0065","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/modpathol.3800612","article-title":"Comprehensive analysis of HE4 expression in normal and malignant human tissues","volume":"19","author":"Galgano","year":"2006","journal-title":"Mod Pathol."},{"key":"10.1097\/IGC.0b013e31821a3726_bb0070","first-page":"111","article-title":"HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses","volume":"11","author":"Abdel-Azeez","year":"2010","journal-title":"Asian Pac J Cancer Prev."},{"key":"10.1097\/IGC.0b013e31821a3726_bb0075","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","article-title":"The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass","volume":"108","author":"Moore","year":"2008","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e31821a3726_bb0080","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ygyno.2010.02.005","article-title":"Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass","volume":"117","author":"Nolen","year":"2010","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e31821a3726_bb0085","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/jnci\/djp438","article-title":"Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study","volume":"102","author":"Anderson","year":"2010","journal-title":"J Natl Cancer Inst."},{"key":"10.1097\/IGC.0b013e31821a3726_bb0090","first-page":"29","article-title":"Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms","volume":"9","author":"Hein","year":"2000","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"10.1097\/IGC.0b013e31821a3726_bb0095","first-page":"3430","article-title":"Elevated caveolin-1 levels in African-American versus white-American prostate cancer","volume":"6","author":"Yang","year":"2000","journal-title":"Clin Cancer Res."},{"key":"10.1097\/IGC.0b013e31821a3726_bb0100","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/sj.bjc.6605011","article-title":"Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts","volume":"100","author":"Huhtinen","year":"2009","journal-title":"Br J Cancer."},{"key":"10.1097\/IGC.0b013e31821a3726_bb0105","first-page":"363","article-title":"Measurement of serum human epididymis secretory protein 4 combined with CA125 assay in differential diagnosis of endometriosis cyst and ovarian benign and malignant tumors","volume":"45","author":"Liu","year":"2010","journal-title":"Zhonghua Fu Chan Ke Za Zhi."},{"key":"10.1097\/IGC.0b013e31821a3726_bb0110","article-title":"The role of serum CA-125 levels and CA-125 tissue expression positivity in the prediction of the recurrence of stage III and IV epithelial ovarian tumors (CA-125 levels and tissue CA-125 in ovarian tumors)","author":"Gundogdu","year":"2010","journal-title":"Arch Gynecol Obstet."},{"key":"10.1097\/IGC.0b013e31821a3726_bb0115","first-page":"931","article-title":"The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy","volume":"43","author":"Dong","year":"2008","journal-title":"Zhonghua Fu Chan Ke Za Zhi."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24045390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24045390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:12:48Z","timestamp":1753233168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24045390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S1048891X24045390"],"URL":"https:\/\/doi.org\/10.1097\/igc.0b013e31821a3726","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human Epididymis Protein 4 (HE4) as a Serum Tumor Biomarker in Patients With Ovarian Carcinoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1097\/IGC.0b013e31821a3726","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright Copyright \u00a9 2011 by IGCS and ESGO.","name":"copyright","label":"Copyright"}]}}